volume 48, issue 2, P188-197 2020
DOI: 10.3899/jrheum.200093
View full text
Uta Kiltz, James Cheng-Chung Wei, Désirée van der Heijde, Filip van den Bosch, Jessica A. Walsh, Annelies Boonen, Lianne S. Gensler, Theresa Hunter, Hilde Carlier, Yan Dong, Xiaoqi Li, Rebecca Bolce, Vibeke Strand, Juergen Braun et al.

Abstract: Objective This study evaluated the effect of ixekizumab on self-reported functioning and health in patients with radiographic axial spondyloarthritis (r-axSpA) who were either biologic disease modifying antirheumatic drugs naïve (bDMARD-naïve) or failed at least 1 tumor necrosis factor inhibitor (TNFi). Methods In 2 multicenter, randomized, double-blind, placebo-controlled, and active-controlled (bDMARD-naïve only) trials, r-axSpA patients were randomly assigned to receive 80 mg of ixekizumab (every 2 weeks [Q…

expand abstract